Company profile
PRELUDE THERAPEUTICS INC
NASDAQ:PRLDBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VENETOCLAX | phase1 | — | 69 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07469891 | phase1 | recruiting | 2026-04-29 | 2028-04-01 | Prelude Therapeutics Incorporated | A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms |
| NCT04837677 | phase1 | completed | 2021-08-11 | 2023-02-06 | Prelude Therapeutics Incorporated | A Study of PRT1419 in Patients With Advanced Solid Tumors |
| NCT04543305 | phase1 | completed | 2020-09-28 | 2022-03-21 | Prelude Therapeutics Incorporated | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies |
| NCT05665530 | phase1 | completed | 2023-09-12 | 2025-06-12 | Prelude Therapeutics Incorporated | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies |
| NCT05159518 | phase1 | completed | 2022-02-14 | 2023-12-06 | Prelude Therapeutics Incorporated | A Study of PRT2527 in Participants With Advanced Solid Tumors |
FDA applications (0)
No records yet.